Brainsway Ltd (BWAY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brainsway Ltd (BWAY) has a cash flow conversion efficiency ratio of -0.010x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-750.96K) by net assets ($78.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Brainsway Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Brainsway Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Brainsway Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Brainsway Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainsway Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
mF International Limited Ordinary Shares
NASDAQ:MFI
|
-0.118x |
|
V-Mart Retail Limited
NSE:VMART
|
0.008x |
|
Kaveri Seed Company Limited
NSE:KSCL
|
-0.083x |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
0.027x |
|
Sequent Scientific Limited
NSE:SEQUENT
|
0.051x |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
0.023x |
|
ADENTRA INC.
F:UQ0
|
N/A |
|
Suli Co Ltd
SHG:603585
|
0.075x |
Annual Cash Flow Conversion Efficiency for Brainsway Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Brainsway Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Brainsway Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.25 Million | $18.16 Million | 0.232x | +40.45% |
| 2024-12-31 | $62.31 Million | $10.30 Million | 0.165x | +435.19% |
| 2023-12-31 | $41.58 Million | $1.28 Million | 0.031x | +114.36% |
| 2022-12-31 | $45.40 Million | $-9.76 Million | -0.215x | -1494.17% |
| 2021-12-31 | $57.33 Million | $884.00K | 0.015x | +121.08% |
| 2020-12-31 | $19.63 Million | $-1.44 Million | -0.073x | +75.55% |
| 2019-12-31 | $24.22 Million | $-7.24 Million | -0.299x | +44.89% |
| 2018-12-31 | $6.95 Million | $-3.77 Million | -0.543x | -99.13% |
| 2017-12-31 | $12.72 Million | $-3.47 Million | -0.273x | -16.72% |
| 2016-12-31 | $10.29 Million | $-2.40 Million | -0.233x | +33.85% |
| 2015-12-31 | $12.89 Million | $-4.55 Million | -0.353x | -44.97% |
| 2014-12-31 | $15.58 Million | $-3.79 Million | -0.244x | -50.97% |
| 2013-12-31 | $14.65 Million | $-2.36 Million | -0.161x | +74.07% |
| 2012-12-31 | $9.01 Million | $-5.60 Million | -0.622x | -- |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, sc… Read more